Bernadette Connaughton - Apr 25, 2024 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
Director
Signature
/s/ James Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Apr 25, 2024
Transactions value $
$0
Form type
4
Date filed
4/29/2024, 05:51 PM
Previous filing
Sep 28, 2023
Next filing
Jun 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Award $0 +6.5K +16.14% $0.00 46.8K Apr 25, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Award $0 +8.8K $0.00 8.8K Apr 25, 2024 Common Stock 8.8K $38.46 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.
F2 Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders.